---
title: "Leqvio (inclisiran), all indications: Specific populations questions"
description: "Specific populations questions on Leqvio (inclisiran) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Leqvio be used during pregnancy? Can Leqvio be used while breastfeeding? Is a Leqvio dose change needed for kidney disease? Is a Leqvio dose change needed for liver disease? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/leqvio/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Leqvio (inclisiran), all indications: Specific populations questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Leqvio](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf)  
Indication pages: [Hypercholesterolemia](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia)

## Pregnancy and breastfeeding

<a id="leqvio-pregnancy"></a>

### Can Leqvio be used during pregnancy?

> “Discontinue LEQVIO when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of 
> the individual patient. Inclisiran increases LDL-C uptake and lowers LDL-C levels in the circulation, thus 
> decreasing cholesterol and possibly other biologically active substances derived from cholesterol; therefore, 
> LEQVIO may cause fetal harm when administered to pregnant patients based on the mechanism of action [see 
> Clinical Pharmacology (12.1)]. In addition, treatment of hypercholesterolemia is not generally necessary during 
> pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during 
> pregnancy should have little impact on the outcome of long-term therapy of hypercholesterolemia for most 
> patients.”

Source: [LEQVIO: Prescribing information, page 4, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=4)

> “There are no available data on the use of LEQVIO in pregnant patients to evaluate for a drug-associated risk of 
> major birth defects, miscarriage or adverse maternal or fetal outcomes.”

Source: [LEQVIO: Prescribing information, page 4, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=4)

> “There is a pregnancy safety study for LEQVIO. Report pregnancies by contacting Novartis at 1-888-669-6682 
> or usdrugsafety.operations@novartis.com.”

Source: [LEQVIO: Prescribing information, page 4, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=4)

<a id="leqvio-breastfeeding"></a>

### Can Leqvio be used while breastfeeding?

> “There is no information on the presence of inclisiran in human milk, the effects on the breastfed infant, or the 
> effects on milk production. Inclisiran was present in the milk of lactating rats in all dose groups. When a drug is 
> present in animal milk, it is likely that the drug will be present in human milk (see Data). Oligonucleotide-based 
> products typically have poor oral bioavailability; therefore, it is considered unlikely that low levels of inclisiran 
> present in milk will adversely impact an infant’s development during lactation. The developmental and health 
> benefits of breastfeeding should be considered along with the mother’s clinical need for LEQVIO and any 
> potential adverse effects on the breastfed infant from LEQVIO or from the underlying maternal condition.”

Source: [LEQVIO: Prescribing information, page 5, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=5)

## Specific populations

<a id="leqvio-kidney"></a>

### Is a Leqvio dose change needed for kidney disease?

> “No dose adjustments are necessary for patients with mild, moderate, or severe renal impairment [see Clinical 
> Pharmacology (12.3)]. LEQVIO has not been studied in patients with end stage renal disease [see Clinical 
> Pharmacology (12.3)].”

Source: [LEQVIO: Prescribing information, page 6, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=6)

> “Despite the higher plasma exposures, 
> reductions in LDL-C were similar across all groups based on renal function.”

Source: [LEQVIO: Prescribing information, page 8, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=8)

<a id="leqvio-liver"></a>

### Is a Leqvio dose change needed for liver disease?

> “No dose adjustment is necessary in patients with mild to moderate hepatic impairment. LEQVIO has not been 
> studied in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].”

Source: [LEQVIO: Prescribing information, page 6, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=6)

> “In patients with moderate hepatic impairment, 
> baseline PCSK9 levels were lower and reductions in LDL-C were less than those observed in patients with 
> normal hepatic function.”

Source: [LEQVIO: Prescribing information, page 8, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=8)

## Related pages
- [Medical information: Leqvio (inclisiran): All indications](https://www.evicenter.com/medical-information/leqvio)
- [Indication](https://www.evicenter.com/medical-information/leqvio/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/leqvio/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/leqvio/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/leqvio/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/leqvio/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/leqvio/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/leqvio/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/leqvio/access-and-coverage)
